Genentech

Genentech to acquire Seragon Pharmaceuticals

Wednesday, July 2, 2014 12:38 PM

Genentech, a member of the Roche Group, will acquire Seragon Pharmaceuticals, a privately held biotechnology company based in San Diego, Calif. Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. 

More... »

WIRB Copernicus Group

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »

CRF Health eCOA webinar series

Coherus Biosciences appoints Lisa M. Bell senior VP, Global Regulatory Affairs

Monday, May 12, 2014 12:41 PM

Coherus Biosciences, a biologics platform company delivering biosimilar therapeutics, has appointed Lisa M. Bell, Ph.D. senior vice president, Global Regulatory Affairs. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies.

More... »

U.S. cancer researchers launching five-drug personalized medicines trial

Monday, April 21, 2014 01:12 PM

U.S. cancer researchers plan to launch a five-drug clinical trial for patients with advanced lung cancer in mid-May, in a public-private collaboration between several major cancer organizations and five pharmaceutical companies that marks the second American multi-drug research program into personalized medicines to treat different cancers.

More... »

Genentech, PatientsLikeMe enter patient-centric research collaboration

Wednesday, April 9, 2014 12:24 PM

PatientsLikeMe, a patient network and a real-time research platform, has formed a five-year agreement with Genentech, a member of the Roche Group, to explore using PatientsLikeMe’s global online patient network to develop innovative ways to research patients’ real-world experiences with disease and treatment. The agreement is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company and provides PatientsLikeMe the opportunity to expand its patient network in oncology.

More... »

Mytrus launches innovation advisory board

Wednesday, March 19, 2014 12:43 PM

Mytrus, a provider of electronic informed consent and e-clinical technologies, has created a new Innovation Advisory Board comprised of industry experts to help shape the future of its clinical products and services.

More... »

FDA approves first medicine with Breakthrough Therapy designation

Monday, November 4, 2013 01:35 PM

Genentech, a member of the Roche Group, has announced that the FDA approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).

More... »

Decision Resources suggests breast cancer market to reach $15B by 2022

Friday, August 23, 2013 11:39 AM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5% annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs